Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

MET positive

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

MET amplification + EGFR mutation (8)

EGFR mutation + MET amplification (5)

ALK rearrangement + MET amplification (3)

EGFR mutation + MET overexpression (3)

MET amplification + MET Exon 14 mutation (3)

MET elevation (3)

MET overexpression + EGFR mutation (3)

BRAF mutation + MET amplification (2)

CD74-ROS1 fusion + MET D1228N + MET amplification (2)

EGFR exon 19 deletion + MET amplification (2)

EGFR exon 19 deletion + MET Amplification + MET D1228V (2)

MET amplification + MET overexpression (2)

PD-L1 overexpression + MET exon 14 mutation (2)

STRN-ALK fusion + MET amplification (2)

ALK rearrangement + MET amplification (1)

CAPZA2-MET fusion + MET amplification (1)

EGFR C797S + MET amplification (1)

EGFR G719D + EGFR L861Q + CUX1-MET fusion (1)

EGFR L747_A750delinsP + MET D1228H + MET D1228N + MET D1228Y + MET Y1230H + MET amplification (1)

EGFR L858R + MET amplification (1)

EGFR L858R + MET overexpression (1)

EGFR L858R + MET positive (1)

EGFR T263P + EGFR L858R + MET amplification (1)

EGFR T790M + MET amplification (1)

EGFR T790M + MET positive (1)

EGFR T790M + STRN-ALK fusion + EGFR amplification + MET amplification (1)

EGFR exon 19 deletion + MET positive (1)

EGFR exon 19 deletion + MET amplification (1)

EGFR exon 19 deletion + MET amplification + MET D1228H + MET D1228N + MET D1228Y (1)

EGFR exon 19 deletion + MET amplification + MET D1228H + MET D1228N + MET D1228Y + MET Y1230C (1)

EGFR exon 19 deletion + TP53 mutation + MET amplification (1)

EGFR mutation + EGFR amplification + MET amplification + MTAP deletion (1)

EGFR mutation + MET amplification + EGFR amplification (1)

EGFR mutation + MET amplification + TP53 mutation (1)

EGFR mutation + MET overexpression + MET amplification (1)

EGFR mutation + MET-CEP7 fusion (1)

EGFR wild-type + MET amplification (1)

EGFR wild-type + MET overexpression (1)

IDH1 R132S + H3K27me3 loss + MET exon 14 skipping mutation (1)

KIAA1549-BRAF fusion + MET amplification (1)

KIF5B-RET fusion + MET amplification (1)

MET amplification + KLC1-ALK fusion (1)

MET amplification + MET exon 14 mutation + EGFR exon 20 insertion (1)

MET amplification + PIK3CA mutation (1)

MET amplification + RB1 wild-type (1)

MET amplification + RET fusion (1)

MET amplification + TP53 mutation (1)

MET amplification + TP53 mutation + SMAD4 mutation + CTNNA1 mutation (1)

MET exon 14 mutation + ALK wild-type (1)

MET exon 14 mutation + EGFR wild-type (1)

MET exon 14 mutation + MET amplification + PD-L1 overexpression (1)

MET exon 14 mutation + MET overexpression (1)

MET mutation + TMB-H (1)

MET negative + EGFR mutation (1)

MET overexpression + EGFR wild-type (1)

MET positive + EGFR mutation (1)

PTGS2 positive + MET positive + PBK positive + EGFR mutation (1)

ROS1 positive + MET amplification (1)

TFE3 rearrangement + MET expression (1)

TP53 mutation + MET amplification + PD-L1 overexpression (1)

MET amplification + EGFR mutation (8)

EGFR mutation + MET amplification (5)

ALK rearrangement + MET amplification (3)

EGFR mutation + MET overexpression (3)

MET amplification + MET Exon 14 mutation (3)

MET elevation (3)

MET overexpression + EGFR mutation (3)

BRAF mutation + MET amplification (2)

CD74-ROS1 fusion + MET D1228N + MET amplification (2)

EGFR exon 19 deletion + MET amplification (2)

EGFR exon 19 deletion + MET Amplification + MET D1228V (2)

MET amplification + MET overexpression (2)

PD-L1 overexpression + MET exon 14 mutation (2)

STRN-ALK fusion + MET amplification (2)

ALK rearrangement + MET amplification (1)

CAPZA2-MET fusion + MET amplification (1)

EGFR C797S + MET amplification (1)

EGFR G719D + EGFR L861Q + CUX1-MET fusion (1)

EGFR L747_A750delinsP + MET D1228H + MET D1228N + MET D1228Y + MET Y1230H + MET amplification (1)

EGFR L858R + MET amplification (1)

EGFR L858R + MET overexpression (1)

EGFR L858R + MET positive (1)

EGFR T263P + EGFR L858R + MET amplification (1)

EGFR T790M + MET amplification (1)

EGFR T790M + MET positive (1)

EGFR T790M + STRN-ALK fusion + EGFR amplification + MET amplification (1)

EGFR exon 19 deletion + MET positive (1)

EGFR exon 19 deletion + MET amplification (1)

EGFR exon 19 deletion + MET amplification + MET D1228H + MET D1228N + MET D1228Y (1)

EGFR exon 19 deletion + MET amplification + MET D1228H + MET D1228N + MET D1228Y + MET Y1230C (1)

EGFR exon 19 deletion + TP53 mutation + MET amplification (1)

EGFR mutation + EGFR amplification + MET amplification + MTAP deletion (1)

EGFR mutation + MET amplification + EGFR amplification (1)

EGFR mutation + MET amplification + TP53 mutation (1)

EGFR mutation + MET overexpression + MET amplification (1)

EGFR mutation + MET-CEP7 fusion (1)

EGFR wild-type + MET amplification (1)

EGFR wild-type + MET overexpression (1)

IDH1 R132S + H3K27me3 loss + MET exon 14 skipping mutation (1)

KIAA1549-BRAF fusion + MET amplification (1)

KIF5B-RET fusion + MET amplification (1)

MET amplification + KLC1-ALK fusion (1)

MET amplification + MET exon 14 mutation + EGFR exon 20 insertion (1)

MET amplification + PIK3CA mutation (1)

MET amplification + RB1 wild-type (1)

MET amplification + RET fusion (1)

MET amplification + TP53 mutation (1)

MET amplification + TP53 mutation + SMAD4 mutation + CTNNA1 mutation (1)

MET exon 14 mutation + ALK wild-type (1)

MET exon 14 mutation + EGFR wild-type (1)

MET exon 14 mutation + MET amplification + PD-L1 overexpression (1)

MET exon 14 mutation + MET overexpression (1)

MET mutation + TMB-H (1)

MET negative + EGFR mutation (1)

MET overexpression + EGFR wild-type (1)

MET positive + EGFR mutation (1)

PTGS2 positive + MET positive + PBK positive + EGFR mutation (1)

ROS1 positive + MET amplification (1)

TFE3 rearrangement + MET expression (1)

TP53 mutation + MET amplification + PD-L1 overexpression (1)

›

MET positive	Solid Tumor	MET positive	Solid Tumor	GST-HG16 Sensitive: C2 – Inclusion Criteria GST-HG16 Sensitive : C2	GST-HG16 Sensitive: C2 – Inclusion Criteria GST-HG16 Sensitive : C2
MET positive	Non Small Cell Lung Cancer	MET positive	Non Small Cell Lung Cancer	ABBV-399 Sensitive: C2 – Inclusion Criteria ABBV-399 Sensitive : C2	ABBV-399 Sensitive: C2 – Inclusion Criteria ABBV-399 Sensitive : C2
MET positive	Squamous Cell Carcinoma of Head and Neck	MET positive	Squamous Cell Carcinoma of Head and Neck	nivolumab Resistant: C3 – Early Trials nivolumab Resistant : C3	nivolumab Resistant: C3 – Early Trials nivolumab Resistant : C3
MET positive	Lung Non-Squamous Non-Small Cell Cancer	MET positive	Lung Non-Squamous Non-Small Cell Cancer	erlotinib + ABBV-399 Sensitive: C3 – Early Trials erlotinib + ABBV-399 Sensitive : C3	erlotinib + ABBV-399 Sensitive: C3 – Early Trials erlotinib + ABBV-399 Sensitive : C3
MET positive	Lung Non-Small Cell Squamous Cancer	MET positive	Lung Non-Small Cell Squamous Cancer	erlotinib + ABBV-399 Sensitive: C3 – Early Trials erlotinib + ABBV-399 Sensitive : C3	erlotinib + ABBV-399 Sensitive: C3 – Early Trials erlotinib + ABBV-399 Sensitive : C3
MET positive	Non Small Cell Lung Cancer	MET positive	Non Small Cell Lung Cancer	erlotinib + LY2875358 Sensitive: C3 – Early Trials erlotinib + LY2875358 Sensitive : C3	erlotinib + LY2875358 Sensitive: C3 – Early Trials erlotinib + LY2875358 Sensitive : C3
MET positive	Gastric Cancer	MET positive	Gastric Cancer	c-MET-targeted CAR-T immunotherapy Sensitive: D – Preclinical c-MET-targeted CAR-T immunotherapy Sensitive : D	c-MET-targeted CAR-T immunotherapy Sensitive: D – Preclinical c-MET-targeted CAR-T immunotherapy Sensitive : D
MET positive	Gastric Cancer	MET positive	Gastric Cancer	tepotinib Sensitive: D – Preclinical tepotinib Sensitive : D	tepotinib Sensitive: D – Preclinical tepotinib Sensitive : D